Arrowhead Research | ARWR - Net Income


Arrowhead Research reported $-132.73M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Moderna USD -1.34B 517M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 3.16B 747M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
TG Therapeutics USD 19.78M 3.26M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026